Dr. Henry Ji, Sorrento Therapeutics’ Chairman and CEO and Scilex Holding Company’s Executive Chairman, to Present at the B. Riley Securities’ 2022 Virtual Neuro & Opthalmology Healthcare Conference (April 27-28, 2022)

On April 25, 2022 Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento") reported that Dr. Henry Ji, Chairman and CEO of Sorrento and Executive Chairman of Scilex Holding Company ("Scilex"), will participate in the B. Riley Virtual Neuro & Opthalmology Healthcare Conference at 10:00AM ET on April 27, 2022 (Press release, Sorrento Therapeutics, APR 25, 2022, View Source [SID1234612912]). Live audio of the event can be accessed by visiting the "Events" page of Sorrento’s website at sorrentotherapeutics.com. Dr. Henry Ji will present on the Neuroscience programs and pipeline for Sorrento and Scilex.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

B. Riley 2022 Virtual Neuro & Opthalmology Healthcare Conference
Presentation will be available on April 27-28, 2022
Presentation Time: 10:00AM – 10:30AM ET or 7:00AM – 7:30AM PT
Webcast Link: View Source
An updated corporate presentation will also be available at www.sorrentotherapeutics.com

Scilex Holding Company and Vickers Vantage Corp. I (Nasdaq: VCKA) ("VCKA"), a special purpose acquisition company sponsored by Vickers Venture Fund VI Pte Ltd and Vickers Venture Fund VI (Plan) Pte Ltd, entered into a definitive business combination agreement ("BCA") on March 17, 2022. Upon the closing of the transaction, the combined company (the "Combined Company") will be renamed Scilex Holding Company, and its common stock is expected to be listed on Nasdaq under the ticker symbol "SCLX". The boards of directors of each of VCKA, Scilex and Sorrento have unanimously approved the proposed transaction. The closing of the transaction, which is expected to occur by the third quarter of 2022, is subject to the approval of VCKA’s shareholders and the satisfaction or waiver of certain other customary closing conditions.

A corporate presentation describing Scilex’s development plans can be found at www.scilexholding.com.